The DUET Study
The DUET study is no longer recruiting participants.Â
Early results from the DUET study suggest that lunsekimig, a new treatment that targets two causes of respiratory inflammation, may help people with chronic rhinosinusitis with nasal polyps (CRSwNP).Â
DUET joins the list of studies demonstrating that the new biologic medicines can benefit people with CRSwNP. Together with other major clinical studies, DUET supports the use of these targeted treatments to improve disease control in CRSwNP.
What was the study investigating?
The DUET Study is an international clinical research study investigating a potential new treatment for adults living with chronic rhinosinusitis with nasal polyps. CRSwNP is a long-term condition involving inflammation in the nose and sinuses and the development of soft swellings called nasal polyps.
The DUET Study investigated an experimental medicine called lunsekimig. Lunsekimig is designed to block two signals involved in respiratory inflammation, with the aim of reducing nasal polyps and improving symptoms.
What did the study show?
Initial results from the DUET Study were announced in April 2026.
The researchers reported that people receiving lunsekimig experienced improvements in three important measures compared with those receiving placebo:
• A reduction in the size and number of nasal polyps
• Reduced nasal congestion and blockage reported by participants
• Improvements in CT scan* measurements indicating that inflammation was reduced.
These improvements were measured after 24 weeks of treatment
These are encouraging initial findings as they suggest that treatment with lunsekimig may help control the underlying disease that causes symptoms of CRS in many people with nasal polyps. However, more detailed results will be needed to understand the full benefits and risks of the treatment.
*A computed tomography (CT) scan is used to create detailed images of the sinuses, helping researchers assess the extent of nasal polyps and sinus inflammation. Find our more about CT scans from the NHS Tests and Treatments Guide.Â
What happens next?
More detailed results from the DUET Study are expected soon and will provide further information about the benefits and safety of lunsekimig.
The results announced so far focus on improvements in nasal polyps, nasal blockage and sinus inflammation. However, the study also measured sense of smell using both a validated smell identification test and patient-reported smell loss scores. We expect that future presentations and publications will provide further detail on these smell-related tests and what they may mean for people living with smell loss associated with nasal polyps.
SmellTaste will continue to follow the research and share further information as it becomes available.
Find out more
Read more about the most recent DUET Study results here.
Read more about the DUET study design and tests here.
Disclosure:
SmellTaste was engaged by Sanofi to support recruitment to the DUET study and to review participant-facing information and materials. SmellTaste received payment from Sanofi for this work.
